Titan Medical Inc. Single Inc isio n Sur ge r y TSX-V: TMD | - - PowerPoint PPT Presentation

▶
titan medical inc
SMART_READER_LITE
LIVE PREVIEW

Titan Medical Inc. Single Inc isio n Sur ge r y TSX-V: TMD | - - PowerPoint PPT Presentation

Dec 22, 2023 210 likes •410 views

Titan Medical Inc. Single Inc isio n Sur ge r y TSX-V: TMD | OTCQX: TITXF May 21, 2013 1 Forward Looking Statements This presentation contains "forward-looking statements" which reflect the current expectations of management of

slide-1
SLIDE 1

1

Titan Medical Inc.

Single Inc isio n Sur ge r y

TSX-V: TMD | OTCQX: TITXF

May 21, 2013

slide-2
SLIDE 2

2

This presentation contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, technological development and implementation, performance and business prospects, opportunities, and illustrations and prototypes of the Amadeus Surgical Systems. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to

  • management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could

cause the Company's actual results, performance, achievements or technological development and implementation to be materially different from any future results, performance, achievements or technological development and implementation that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated April 10, 2013 and other information contained in the Company’s public filings (which may be viewed at www.sedar.com). Information contained in this presentation is qualified in its entirety by such public filings. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the presentation are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward- looking statements. This presentation does not constitute an offer to sell any class of securities of the Company in any jurisdiction.

Forward Looking Statements

slide-3
SLIDE 3

3

  • Titan Medical is developing a Single Incision Surgery platform to provide

clear competitive advantages

  • Over $30 MM invested in research and development

– Single Incision Surgery insertion through ~25mm access – High dexterity computer assisted instruments – Force-feedback control and surgical simulation

  • Differentiated technology with growing IP portfolio
  • Attractive financial model – “Razor / Razorblade”
  • Single Incision Surgery scheduled for launch outside the US in 2015

Titan Medical Overview

slide-4
SLIDE 4

4

  • Shorter hospitalization
  • Reduced pain
  • Faster recovery times
  • One incision, reducing risk of

infection, blood loss and scarring

  • Magnified 3D vision for anatomic

viewing

  • Precision, control and range of

motion of micro-instruments

  • Improved access to organs, tissues

and nerves with high dexterity instruments

For The Surgeon For The Patient

  • Answers the challenge of:
  • Increased efficiency
  • Operating room utilization
  • Cost of entry into surgical robotics
  • Return on investment of capital equipment

For The Hospital

Single Incision Surgery benefits

slide-5
SLIDE 5

5

Single Incision Surgery

Open Surgery Multi-port Surgery Single Incision Surgery

  • Titan Advantages:

– Single Incision 25mm access – Improved instrument dexterity and reach – 3D HD visualization – Small footprint providing easy setup and maneuverability – Capital cost ~$600K

I ma g e So urc e s: Co lumb ia Unive rsity; Sina i Surg e ry Asso c ia te s, Mo unt Sina i Me dic a l Ce nte r, Ne w Yo rk

slide-6
SLIDE 6

6

  • Over 3.2 million newly diagnosed cases

each year

  • ~450,000 robotic surgeries in 2012
  • Hysterectomy and Prostatectomy

represent 75% of those surgeries

  • Titan’s Single Incision Surgery system to

initially target General Surgery

  • Estimated annual market to exceed $4

Billion*

Market Opportunity

So urc e : Ame ric a n Ca nc e r So c ie ty, pub lic c o mpa ny filing s

Colon & Rectal 142,570 4% Cardiac 370,000 12% Urology 322,000 10% GYN 824,000 26% Thoracic 258,520 8% ENT 285,020 9% General Surgery 1,000,000 31%

* Ro b o tic surg e ry wa s first c o mme rc ia lly intro duc e d in the ye a r 2000, a nd in te n ye a rs ha s g ro wn to a $1 b illio n industry. E stima te s sug g e st tha t the Ro b o tic Surg e ry E q uipme nt Ma nufa c turing industry re ve nue is pro je c te d to inc re a se a t a n a ve ra g e a nnua l ra te o f 14.9% to $4.2 b illio n in the thre e ye a rs to 2016. So urc e : Pub lic c o mpa ny filing s, I BI S Wo rld

slide-7
SLIDE 7

7

GYN Uro lo g y Ca rdia c

Cur r e ntly Addr e sse d Mar ke t T itan Me dic al Oppor tunity

GYN

Hyste re c to my 600,000

Ur

  • logy

Pro sta te c to my 200,000 So urc e : Ame ric a n Ca nc e r So c ie ty, pub lic c o mpa ny filing s

Addressable Opportunity

Genera l Surg ery E NT C a rd ia c T ho ra c ic

E NT

T hyro id Ca nc e r 44,670 Ba se o f T

  • ng ue Ca nc e r 10,990

L a ryng e a l Ca nc e r 12,720 E so pha g e a l Ca nc e r 16,640 T

  • nsille c to my 200,000

Co lo n & Re c ta l Co lo n & Re c ta l

Ge ne r al Sur ge r y

Cho le c yste c to my 750,000 Appe nde c to my 250,000

T ho ra c ic

GYN

Hyste re c to my 600,000

Ur

  • logy

Pro sta te c to my 200,000

slide-8
SLIDE 8

8

  • A computer assisted platform for Single Incision Surgery
  • Addresses unmet surgical needs technically and economically

Titan’s Single Incision Surgery

I ma g e s fo r illustra tio n purpo se s o nly a nd a re sub je c t to c ha ng e Ope ra ting Ro o m

slide-9
SLIDE 9

9

  • Features include:

– Deployment of system into body cavity through a ~25 mm skin incision – High dexterity 7DOF computer assisted instruments – Stereoscopic 3D HD controllable camera – Full array of surgical tools (capable

  • f delivering electro-cautery for

hemostasis) – Small refined workstation

Titan’s Single Incision Surgery

slide-10
SLIDE 10

10

Phase 1 Phase 2 Phase 3 Phase 4

Development Plan

Research & Early Development

  • Voice of the customer and market research
  • Articulating Instruments
  • Console with Force-Feedback

Licensing Activity

  • IREP from Columbia University for

single-site access surgery

  • Assess functionality of existing development/prototypes and specifications
  • Concept development and prototypes for each critical area sub-component

R&D Commercialization

  • Generate fully specified design and system-level prototype
  • Perform animal and cadaver testing
  • Conduct final prototype builds and design verification testing
  • Complete and submit necessary regulatory packages
  • Transfer completed system design to manufacturing
  • Ready for commercialization

Current

slide-11
SLIDE 11

11

Key Milestones

Catalysts Increasing Shareholder Value

U.S. Initia tion of Huma n Clinic a l T r ia ls Outside U.S. Appr

  • vals

(CE Ma r k)

2H 2013 2H 2014 2H 2014 2H 2015

F DA 510(K) Appr

  • val

Initia tion of Sing le Inc ision syste m for Ca da ve r a nd Anima l Studie s Outside U.S. Ma r ke t L a unc h

1H 2015

slide-12
SLIDE 12

12

Intellectual Property

Patents & Patent Applications Licensed Technology

  • 7 U.S. Patents

– 8,332,072 8,347,754 8,306,656 8,224,485 6,358,196 5,593,379 5,529,568

  • 10 Patent Applications (U.S. and PCT)
  • Licensed Technology

– Exclusive rights to 4 patent applications presently pending before patent offices in the U.S., Canada and/or Europe – Covering technology related to:

  • Surgical Stapler from the Mayo Foundation
  • Insertable Robotic Effector Platform ("IREP") for single-site robotic surgery

from Columbia University

slide-13
SLIDE 13

13

Clinical Site Partners

slide-14
SLIDE 14

14

One T ime Se r vic e Agr e e me nts

~$50,000 pe r ye a r

  • High recurring revenue to be generated by disposable components
  • Reasonable profit margins
  • Proven business model in the market

Business Model

Disposable Instr ume nts Syste m Sale s

6,000 pla c e me nt

  • ppo rtunitie s wo rldwide

Re c ur r ing Re ve nue

slide-15
SLIDE 15

15

T ic ke r symb o l T MD (T SX Ve nture ), T I T XF (OT CQX) Sha re pric e - T MD (Ma y 21, 2013) $0.55 Ca sh a nd c a sh e q uiva le nts (Ma rc h 31, 2013) $8,563,033 Curre nt b urn ra te (Ma rc h 31, 2013) $500,000 - $700,000 pe r mo nth Sha re s o utsta nding (Ma rc h 31, 2013) 71,213,411 (72,807,829* F D) Ma rke t va lue (Ma y 21, 2013) $39,167,376 ($40,044,306* F D) Se c urity o ffe ring s:

  • Ma rc h 2013
  • Ma rc h 2012
  • De c e mb e r 2011
  • June 2011
  • De c e mb e r 2010

6,260,763 units ($6,573,801 g ro ss pro c e e ds) 1,986,755 units ($3,000,000 g ro ss pro c e e ds) 4,880,000 units ($7,564,000 g ro ss pro c e e ds) 5,577,500 units ($9,202,875 g ro ss pro c e e ds) 5,000,000 units ($8,250,000 g ro ss pro c e e ds) Ma na g e me nt o wne rship (Ma rc h 31, 2013) 14.92%

*Fully diluted includes, under the Treasury Stock method, an additional 2,440,287 options with a weighted-average exercise price of $0.58. In addition, 5,000,000 warrants (@$1.85 expiring December 10, 2015), 5,577,500 warrants (@$2.00 expiring June 10, 2016), 4,880,000 warrants (@$1.75 expiring December 22, 2016), 1,986,755 warrants (@$1.77 expiring March 14, 2017) and 6,260,733 warrants (@$1.25 expiring March 31, 2018) are outstanding.

Financial Snapshot

slide-16
SLIDE 16

16

Na me & Position Ba c kg r

  • und

John Har gr

  • ve

CE O

  • Ove r 30 ye a rs o f e xe c utive -le ve l he a lth c a re e xpe rie nc e with the ma jo rity spe nt

with Jo hnso n a nd Jo hnso n in the o pe ra ting c o mpa nie s o f E thic o n, E thic o n E nd o - Surg e ry a nd Jo hnso n a nd Jo hnso n He a lth Ca re Syste ms

  • Pre vio us po sitio ns inc lud e Vic e -Pre sid e nt o f Co rpo ra te Ac c o unts fo r Jo hnso n &

Jo hnso n a nd Pre sid e nt, Co rpo ra te Ac c o unt Ma na g e me nt fo r Ohme d a Inc .

Re iza Rayman, MD, PhD

Pre sid e nt

  • Clinic a l re se a rc h in ro b o tic surg e ry sinc e 1998
  • Co lla b o ra te d in wo rld ’ s first e nd o sc o pic ro b o tic c o ro na ry a rte ry b ypa ss (1999)
  • No rth Ame ric a ’ s first surg ic a l te le me nto ring
  • Ob ta ine d $30M g ra nt fo r ro b o tic surg e ry
  • Autho r a nd c o -a utho r o f mo re tha n 20 pub lic a tio ns o n ro b o tic surg e ry

Ste phe n Randall, CGA

CF O

  • Se rve d a s a n a ud ito r, CF

O, c o rpo ra te c o ntro lle r a nd a c c o unta nt fo r se ve ra l pub lic a nd priva te c o mpa nie s a nd g o ve rnme nt o rg a niza tio ns

  • E

xpe rie nc e in ta x pla nning / c o mplia nc e , M&A, IT & o pe ra tio ns

Joe T alar ic o, JD

VP, Busine ss De ve lo pme nt

  • Va rio us po sitio ns with Intuitive Surg ic a l Inc ., inc lud ing Are a T

ra ining Dire c to r, Clinic a l Sa le s Ma na g e r, Are a Sa le s Ma na g e r a nd Clinic a l Sa le s Re pre se nta tive (2004-2009)

  • T

e rrito ry Ma na g e r fo r U.S. Surg ic a l Co rpo ra tio n tra ining a nd se lling la pa ro sc o pic e q uipme nt (2003-2004)

John Valvo, MD

VP, Me d ic a l Affa irs

  • E

xe c utive Dire c to r o f Ro b o tic a nd Minima lly Inva sive Surg e ry a nd fo rme r Chie f o f Uro lo g y a t Ro c he ste r Ge ne ra l Ho spita l in Ro c he ste r, Ne w Yo rk

  • F
  • und e r o f the ro b o tic pro g ra m a t Ro c he ste r Ge ne ra l Ho spita l
  • Ha s pe rfo rme d o ve r 600 ro b o tic pro sta te c to mie s

Management Team

slide-17
SLIDE 17

17

Medical Advisors

Na me Ba c kg r

  • und

Douglas Boyd, MD

  • Co mple te d wo rld ’ s first ro b o tic b e a ting he a rt c a rd ia c b ypa ss surg e ry
  • Dire c to r o f Ro b o tic s & Pro fe sso r o f Ca rd io tho ra c ic Surg e ry a t UC Da vis

Bob Kiaii, MD

  • Re se a rc h a c tivity inc lud e s ro b o tic -a ssiste d c a rd ia c surg e ry, ha rve sting o f a rte ria l

c o nd uits fo r MIS a nd ro b o tic c a rd ia c surg e ry

Hie p T hie u Nguye n, MD

  • Asso c ia te Pro fe sso r in Surg e ry (Uro lo g y) a t Ha rva rd Me d ic a l Sc ho o l a nd the

Dire c to r o f Ro b o tic Surg e ry, Re se a rc h a nd T ra ining Ce nte r a t Child re n's Ho spita l, Bo sto n

David M. Albala, MD

  • Chie f o f Uro lo g y a t Cro use Ho spita l in Syra c use , Ne w Yo rk a nd Me d ic a l Dire c to r

fo r Asso c ia te d Me d ic a l Pro fe ssio na ls

  • Ove r 20 ye a rs o f la pa ro sc o pic a nd ro b o tic uro lo g ic a l surg e ry e xpe rtise

L

  • uis E

ic he l, MD

  • E

xte nsive b a c kg ro und in re se a rc hing the c linic a l a spe c ts o f surg ic a l ro b o tic s a nd surg ic a l simula tio n

  • Curre ntly pra c tic e s in Ro c he ste r, Ne w Yo rk a nd is a Clinic a l Assista nt Pro fe sso r o f

Uro lo g y a t the Unive rsity o f Ro c he ste r

Po N. L am, MD

  • Spe c ia lize s in o nc o lo g ic ro b o tic a nd la pa ro sc o pic surg e ry in Ce ntra l Ne w Yo rk
  • Ha s pe rfo rme d o ve r 500 ro b o tic surg e rie s sinc e 2006

Car lo Camar go Passe r

  • tti,

MD, PhD

  • Assista nt Pro fe sso r o f Uro lo g y a t the Sa o Pa ulo Sta te Unive rsity, Dire c to r o f

Ro b o tic Surg e ry a t the Ho spita l Ale mã o Oswa ld o Cruz, a nd Dire c to r o f Re se a rc h in Uro lo g y, Unive rsity o f Sa o Pa ulo , Bra zil

slide-18
SLIDE 18

18

Medical Advisors (cont’d)

Na me Ba c kg r

  • und

E r ic J. Moor e , MD

  • Asso c ia te Pro fe sso r o f Oto la ryng o lo g y (E

NT ) a t Ma yo Clinic

  • Re se a rc h inc lud e s o ro pha ryng e a l c a nc e r, tra nso ra l ro b o tic surg e ry fo r he a d a nd

ne c k c a nc e r, he a d a nd ne c k mic ro va sc ula r re c o nstruc tio n, no ve l d e te c tio n a nd tre a tme nt me tho d s fo r pa pillo ma virus ind uc e d o ro pha ryng e a l c a nc e r

  • Na me d in o ve r 30 pub lic a tio ns, c e rtifie d b y the Ame ric a n Bo a rd o f F

a c ia l Pla stic a nd Re c o nstruc tive Surg e ry a nd Ame ric a n Bo a rd o f Oto la ryng o lo g y

L i- Ming Su, MD

  • Da vid A. Co frin Pro fe sso r o f Uro lo g y, Asso c ia te Cha irma n fo r Clinic a l Affa irs a nd

the Dire c to r o f Ro b o tic a nd Minima lly Inva sive Uro lo g ic Surg e ry in the De pa rtme nt o f Uro lo g y a t the Unive rsity o f F lo rid a Co lle g e o f Me d ic ine in Ga ine sville , F lo rid a

  • Are a s o f surg ic a l spe c ia lty inc lud e ro b o tic pa rtia l ne phre c to my, ne rve -spa ring

ra d ic a l pro sta te c to my, pye lo pla sty, ne phro ure te re c to my a nd a d re na le c to my

Balasubr amanian Sivakumar , MD

  • Vic e Pre sid e nt o f St. Jo se ph's Ho spita l He a lth Ce nte r in Syra c use , NY a nd

Pre sid e nt e le c t o f the me d ic a l sta ff fo r 2012

  • Ro b o tic surg e ry pro c to r/ me nto r who tra ine d nume ro us surg e o ns pra c tic ing

ro b o tic surg e ry in spe c ia ltie s inc lud ing Ge ne ra l Surg e ry; Ca rd ia c Surg e ry; Uro lo g ic Surg e ry; T ho ra c ic Surg e ry, a nd Gyne c o lo g ic Surg e ry

T e r r y W. Gr

  • gg, MD
  • Clinic a l instruc to r fo r re sid e nt e d uc a tio n a t Mo unt Ca rme l We st a nd a t T

he Ohio Sta te Unive rsity sinc e 1992, a nd pa rtne r a t So uthwe ste rn Ob ste tric s a nd Gyne c o lo g y, a d ivisio n o f MOCA, a priva te pra c tic e

  • Ma in c linic a l a nd surg ic a l re se a rc h inte re sts in Minima lly Inva sive Surg e ry inc lud e

hyste re c to mie s, myo me c to mie s, e xc isio n o f e nd o me trio sis, unila te ra l sa lping o

  • o phe re c to my, b ila te ra l sa lping o o o phe re c to my, a nd sa c ro c o lpo pe xy